No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Rakovina Therapeutics Unveils Preclinical Data at the AACR - World's Premier Cancer Research Forum
Next-Gen Cancer Treatment: Rakovina's AI-Driven ATR Inhibitors Enter Preclinical Testing
Rakovina Therapeutics and Variational AI Strengthen Partnership
Rakovina Therapeutics Announces Additional Synthesized Compounds in Its AI-Driven Cancer Drug Discovery Program
Rakovina Therapeutics Announces Listing on Frankfurt Stock Exchange
Rakovina Therapeutics to Participate in BioInnovate UBC Annual Conference